New combo aims to stop liver cancer recurrence in High-Risk patients

NCT ID NCT04418401

Completed Disease control Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested whether combining donafinib (a targeted therapy) with an anti-PD-1 antibody (an immunotherapy) can safely prevent liver cancer from coming back after surgery. It involved 30 patients with high-risk features like microvascular invasion or multiple tumors. The goal was to see if this approach improves the one-year recurrence-free rate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Donafinib and anti-PD-1 antibody
What this could lead to: If successful, this combination could reduce the chance of liver cancer returning after surgery, offering a new option for high-risk patients.
What could go wrong: This is an early Phase 1 trial with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to prevent recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

the First Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.